4.7 Article

The effect of dipeptidyl peptidase IV on disease-associated microglia phenotypic transformation in epilepsy

期刊

JOURNAL OF NEUROINFLAMMATION
卷 18, 期 1, 页码 -

出版社

BMC
DOI: 10.1186/s12974-021-02133-y

关键词

Disease-associated microglia; Dipeptidyl peptidase IV; Epilepsy; Microglia

资金

  1. Natural Science Foundation of Hubei Province of China [2017CFA017]
  2. Wuhan Science and Technology Project [2019020701011444]
  3. Medical Science Advancement Program of Wuhan University [TFJC2018001, TFLC2018001]
  4. Hubei Provincial Natural Science Foundation of China [2019CFB482]
  5. National Natural Science Foundation of China [NSFC81100594]

向作者/读者索取更多资源

The study revealed that DPP4 is involved in DAM conversion and epilepsy, and treatment with DPP4 inhibitor sitagliptin can alleviate epilepsy and promote DAM phenotypic transformation, resulting in enhanced morphological features and functions of microglia.
Background Accumulating evidence suggests that disease-associated microglia (DAM), a recently discovered subset of microglia, plays a protective role in neurological diseases. Targeting DAM phenotypic transformation may provide new therapeutic options. However, the relationship between DAM and epilepsy remains unknown. Methods Analysis of public RNA-sequencing data revealed predisposing factors (such as dipeptidyl peptidase IV; DPP4) for epilepsy related to DAM conversion. Anti-epileptic effect was assessed by electroencephalogram recordings and immunohistochemistry in a kainic acid (KA)-induced mouse model of epilepsy. The phenotype, morphology and function of microglia were assessed by qPCR, western blotting and microscopic imaging. Results Our results demonstrated that DPP4 participated in DAM conversion and epilepsy. The treatment of sitagliptin (a DPP4 inhibitor) attenuated KA-induced epilepsy and promoted the expression of DAM markers (Itgax and Axl) in both mouse epilepsy model in vivo and microglial inflammatory model in vitro. With sitagliptin treatment, microglial cells did not display an inflammatory activation state (enlarged cell bodies). Furthermore, these microglia exhibited complicated intersections, longer processes and wider coverage of parenchyma. In addition, sitagliptin reduced the activation of NF-kappa B signaling pathway and inhibited the expression of iNOS, IL-1 beta, IL-6 and the proinflammatory DAM subset gene CD44. Conclusion The present results highlight that the DPP4 inhibitor sitagliptin can attenuate epilepsy and promote DAM phenotypic transformation. These DAM exhibit unique morphological features, greater migration ability and better surveillance capability. The possible underlying mechanism is that sitagliptin can reduce the activation of NF-kappa B signaling pathway and suppress the inflammatory response mediated by microglia. Thus, we propose DPP4 may act as an attractive direction for DAM research and a potential therapeutic target for epilepsy.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据